Thymalin: A Soviet-Era Thymus Peptide for Immune Rejuvenation, Examined
Thymalin is a Russian thymus-peptide immunomodulator with intriguing COVID and ageing data — but the evidence comes almost entirely from one research group.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-17A thymus-peptide complex with a coherent immunomodulatory rationale and some eye-catching non-randomised COVID-19 and geroprotection signals, but almost the entire evidence base traces to a single research lineage using small, non-randomised, often unblinded designs; it is unapproved outside Russia, and clinically meaningful benefit remains unproven.
Plausible immunomodulatory rationale (thymus-peptide-driven T-cell differentiation and cytokine modulation), but the molecular account — peptides binding dsDNA to regulate cytokine genes — is characterised almost entirely by the originating group.
Limited and single-lineage: an in-vitro stem-cell-differentiation result plus rat tumour and bone-healing studies, not independently replicated.
Only small, non-randomised or open-label cohorts (COVID-19, geroprotection) from the originating lineage; no randomised controlled trials.
The striking cohort figures (e.g. roughly halved mortality, long-run geroprotection) are non-randomised and confounded, so clinically meaningful benefit is not established.
Minimal: an animal-derived, non-standardised biological with no robust long-term human safety data outside the Russian label.
Registered in Russia since 1982, but the international evidence base is early and confined to one research lineage, with no registered modern trials elsewhere.
Single-lineage, weak-design evidence keeps confidence low.
Not approved by the FDA, EMA or MHRA; realistic supply outside Russia is unregulated 'research-only' injectable, and it is an animal-derived biological of unstandardised composition.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A thymus-derived peptide complex registered as a medicine in Russia since 1982, with a coherent immunomodulatory rationale and some eye-catching non-randomised COVID-19 and geroprotection signals — but almost the entire evidence base traces to a single research lineage using weak designs, with no independent replication.
Safety snapshot
An animal-derived, non-standardised biological with no robust long-term human safety data outside the Russian label; immunomodulation is double-edged in autoimmune disease, malignancy or on immunosuppressants, and Western supply is unregulated injectable.
Regulatory & legality
Registered only in Russia (a Soviet-era registration); not approved by the FDA, EMA or MHRA, where the realistic supply is grey-market 'research-only' product.
Where claims can exceed the evidence
Clinically meaningful benefit is unproven — the striking cohort figures are non-randomised and confounded — and longevity claims are not established.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Thymalin is one of the oldest peptide bioregulators still in circulation. It is a polypeptide complex extracted from calf (bovine) thymus, developed in 1970s–80s Leningrad by Vladimir Khavinson and Vyacheslav Morozov, and registered as an immunomodulatory medicine in the USSR back in 1982. In longevity and biohacking circles it is marketed as a thymus-restoring, "immune rejuvenation" peptide — often stacked alongside Epitalon and other Khavinson peptides.
Here is the honest framing up front: nearly the entire evidence base traces back to a single Russian research lineage centred on the St. Petersburg Institute of Bioregulation and Gerontology. That is a substantial limitation. Most human reports are small, non-randomised or open-label, published in Russian or low-impact journals, and have not been independently replicated by Western groups. The mechanistic story is biologically plausible, and some of the modern COVID-19 data is genuinely interesting — but none of it rises to the level of rigorous, independent proof. Treat what follows as emerging, not established.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
PNC-27: The Cancer-Killing Peptide That Hasn't Met a Human Trial
A plain-English, evidence-first look at PNC-27: a clever pore-forming anti-cancer peptide with two decades of lab work but zero registered human trials.
Thymosin Alpha-1: The Immune Modulator With a Real Clinical Track Record
Thymosin alpha-1 has decades of human use and 30+ trials behind it. We unpack where the evidence is genuinely strong, where it is thin, and what it actually does.
VIP (Vasoactive Intestinal Peptide): Strong Biology, Weak Human Proof
VIP has compelling anti-inflammatory mechanisms in animals, but rigorous human trials have largely failed. Here's the honest evidence picture.